Numinus Launches Psychedelic Program for Mental Distress
Numinus Wellness (OTC: NUMIF) has launched an innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. The program will operate out of the Numinus Wellness and Cedar Clinical Research facilities in Utah.
Dr. Paul Thielking, Chief Science Officer at Numinus, said, “Through our innovative psychedelic program for serious and chronic illness, Numinus is spearheading a new era of transformative care. By harnessing the potential of psilocybin and ketamine-assisted therapies, we are providing hope and healing to individuals in need. We are excited to continue our innovative work and contribute to the advancement of psychedelic-assisted therapies for the betterment of patients worldwide.”
Highlights
Numinus’ program encompasses four key initiatives, including studying the efficacy of group-administered psilocybin for depressed cancer patients.
In an FDA and IRB approved study, Numinus will initiate a follow-up group psilocybin project which will reduce the therapist to patient ratio while continuing to evaluate the impact of psilocybin-assisted therapy on cancer patients with depression.
The company has also completed a group ketamine-assisted therapy intervention pilot for subjects suffering from chronic and serious illnesses. This pilot project showcased the effectiveness of ketamine-assisted therapy in alleviating depression and psychological distress associated with these conditions.
Numinus is honored to be selected as one of five different sites participating in the Ketamine Research Foundation’s sponsored research study on ketamine to reduce end of life distress.
About Numinus Wellness
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
